CagriSema vs. Tirzepatide: A Head-to-Head for Diabetes and Weight Loss
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Background
Type 2 Diabetes Mellitus is a chronic metabolic condition characterized by high blood sugar levels, often accompanied by obesity. Current treatments like metformin and SGLT2 inhibitors help manage the disease, but many patients still struggle to achieve optimal glycemic control and weight reduction. This study addresses the need for more effective therapeutic options by directly comparing a novel co-formulation, CagriSema, against the established dual-agonist tirzepatide.